City Therapeutics, Inc. (NASDAQ:CTY – Get Free Report) saw a significant growth in short interest in October. As of October 30th, there was short interest totaling 822,840 shares. Based on an average trading volume of 361,905 shares, the short-interest ratio is presently 2.3 days. Approximately 1.6% of the shares of the stock are short sold.
Insiders Place Their Bets
In other news, Director Robert Nelsen bought 170,000 shares of the business’s stock in a transaction dated Monday, October 19th. The shares were purchased at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the completion of the acquisition, the director owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc acquired 170,000 shares of the firm’s stock in a transaction on Monday, October 19th. The stock was purchased at an average price of $18.00 per share, for a total transaction of $3,060,000.00. Following the transaction, the insider directly owned 13,692,507 shares of the company’s stock, valued at approximately $246,465,126. This trade represents a 1.26% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.
Analysts Set New Price Targets
CTY has been the topic of a number of research reports. Stifel Nicolaus initiated coverage on shares of City Therapeutics in a report on Tuesday, November 10th. They set a “buy” rating and a $34.00 target price on the stock. Oppenheimer began coverage on City Therapeutics in a report on Tuesday, November 10th. They issued an “outperform” rating and a $46.00 target price for the company. Zacks Research began coverage on City Therapeutics in a report on Wednesday, November 11th. They set a “hold” rating on the stock. Jefferies Financial Group assumed coverage on City Therapeutics in a research report on Tuesday, November 10th. They set a “buy” rating and a $32.00 target price on the stock. Finally, Wall Street Zen raised City Therapeutics to a “hold” rating in a research note on Saturday, October 24th. Three equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $37.33.
City Therapeutics Price Performance
Shares of CTY stock traded down $1.17 on Monday, reaching $16.93. 62,428 shares of the company’s stock were exchanged, compared to its average volume of 279,418. City Therapeutics has a 52 week low of $15.81 and a 52 week high of $23.88.
About City Therapeutics
City Therapeutics is a biotechnology company developing medicines based on RNA interference (RNAi), a biological process that can reduce the production of specific disease-related proteins. Its research focuses on designing RNAi therapies for potential use across a range of diseases. Launched in 2024, the company is developing technology intended to advance the design and delivery of RNAi medicines. Its work is research and development focused; the company’s activities center on building a therapeutic pipeline rather than marketing established products.
Recommended Stories
- Five stocks we like better than City Therapeutics
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
- Could Big Buybacks Be the Next Catalyst for These 3 AI Stocks?
- 3 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?
Receive News & Ratings for City Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for City Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
